Auto-SCT improves survival in systemic light chain amyloidosis: A retrospective analysis with 14-year follow-up

Bone Marrow Transplantation

Volumn 49, Issue 8, 2014, Pages 1036-1041

  Parmar, S ^a   Kongtim, P ^a   Champlin, R ^a   Dinh, Y ^a   Elgharably, Y ^a   Wang, M ^a   Bashir, Q ^a   Shah, J J ^a   Shah, N ^a   Popat, U ^a   Giralt, S A ^b   Orlowski, R Z ^a   Qazilbash, M H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; PREDNISONE; THALIDOMIDE; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; COMPARATIVE STUDY; CONTROLLED STUDY; CONVENTIONAL THERAPY; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HUMAN; INDUCTION CHEMOTHERAPY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LIGHT CHAIN AMYLOIDOSIS; TREATMENT RESPONSE; VERY ELDERLY; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; STEM CELL TRANSPLANTATION; TIME;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 84905687805     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.115     Document Type: Article

References (36)

1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933.
2. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.
3. Gertz MA. I don't know how to treat amyloidosis. Blood 2010; 116: 507-508.
4. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
5. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949-2951.
6. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457-464.
7. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465-470.
8. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492-496.
9. Dimopoulos MA, Kastritis E. Bortezomib for AL amyloidosis: moving forward. Blood 2011; 118: 827-828.
10. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and highdose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 2011; 96: 1890-1892.
11. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free lightchain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597-600.
12. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543-551.
13. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
14. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093.
15. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-642.
16. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012; 119: 1117-1122.
17. Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL et al. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant 2013; 49: 434-439.
18. Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant 2009; 15: 893-902.
19. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R et al. Modified high-dose melphalan and autologous SCT for AL amyloidosis or highrisk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant 2013; 48: 1537-1542.
20. Rosenzweig M, Giralt S, Landau H. Light-chain amyloidosis: SCT, novel agents and beyond. Bone Marrow Transplant 2013; 48: 1022-1027.
21. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
22. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 57-65.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53 457-481.
24. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
25. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
26. Ogura M, Sekine R, Nishiyama S, Abe Y, Iizuka H, Kusaka S et al. [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis]. Rinsho Ketsueki 2012; 53: 710-715.
27. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 36-41.
28. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N et al. Refinement in patient selection to reduce treatment-related mortality from SCT in amyloidosis. Bone Marrow Transplant 2012; 48: 557-561.
29. Bleeker JS, Gertz MA, Pellikka PA, Larson DR, Buadi F, Dingli D et al. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. Eur J Haematol 2012; 89: 228-235.
30. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394.
31. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006; 108: 3945-3947.
32. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86: 12-18.
33. Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Hayman SR, Buadi F et al. Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. Amyloid 2011; 18(Suppl 1): 137-138.
34. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Buadi FK, Dingli D et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011; 46: 970-975.
35. Chaulagain CP, Comenzo RL. New insights and modern treatment of Al amyloidosis. Curr Hematol Malig Rep 2013; 8: 291-298.
36. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013; 98: 433-436